Loading...
•
Mar 31, 2021
NeoGenomics Q1 2021 Earnings Report
NeoGenomics reported revenue growth and strategic acquisitions.
Key Takeaways
NeoGenomics reported a 9% increase in consolidated revenue to $116 million for the first quarter of 2021. The company completed the acquisition of Trapelo Health in April and announced the acquisition of Inivata. However, the company's net loss increased to $22 million, and adjusted EBITDA decreased to $4 million.
Consolidated revenue increased by 9% to $116 million.
Clinical Services revenue increased by 4% to $96 million.
Pharma Services revenue increased by 46% to $19 million.
Completed the acquisition of Trapelo Health in April.
Forward Guidance
The company issued 2021 guidance with consolidated revenue between $490 million and $510 million, net loss between $(70) million and $(65) million, and adjusted EBITDA between $10 million and $15 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...